On the stock market since 2014, it operates in the world of health and science. It has 5 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 55% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
An investor who bought at the very peak is down 89% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $40K a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 9 buys and 7 sells. Management buying with its own money is usually read as a good sign.
A loss of $10.3M against $40K in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
The stock trades 93% above the average analyst price target.
On our five-subject report card, BSGM sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: BSGM is a small company that closed last year at a loss. The road back to profit runs through spending discipline.